Online Broker Libertex Becomes the Official Online Trading Partner of FC Bayern
Libertex, one of the leading online trading platforms and part of the Libertex Group founded in 1997, is entering into a multi-year partnership with Germany's most successful football club. Not only is this the first time FC Bayern has worked with an Online Trading Partner in the field of CFD and foreign exchange trading (B2C sector), but it is also the first time Libertex has sponsored a German club alongside its existing commitments in the Premier League.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005297/en/
From left to right: Michael Geiger (CEO, Libertex), Marios Chailis (CMO, Libertex Group), Andreas Jung (FC Bayern board member for marketing). (Photo: FC Bayern)
"With over 290,000 members, FC Bayern is the sports club with the biggest membership worldwide. Like their club, the fans are particularly hungry for success, but also show themselves to be fair and level-headed after defeats, which impressed us“ says Michael Geiger, CEO of Libertex. "We are delighted to be the Official Online Trading Partner of Germany's most successful club with immediate effect."
By combining the fast-paced and exciting worlds of football and trading, the partnership allows Libertex to share its love of the game and healthy competition with its millions of customers. FC Bayern's self-image is to stand for an extreme winning mentality and a good shot of self-confidence, just like the motto - If you want to win, you have to work hard for it! Similarly, Libertex's motto 'Trade For More', as Libertex Group CMO Marios Chailis explains: "Trading also requires a certain amount of self-confidence, while being aware that arrogance has no place in trading; and you need to acquire enough knowledge to avoid making the wrong decisions. That's why we support our clients on these and other points, for example by offering a demo account and other educational material."
Andreas Jung, FC Bayern board member for marketing: “Libertex is an innovative company in an emerging global market. We look forward to building a constructive partnership with one of the leading online trading platforms for experienced traders.”
As the Official Online Trading Partner of FC Bayern, Libertex will now be part of the LED perimeter advertising at Munich's Allianz Arena and will also have a regular presence on FC Bayern's social media channels.
About Libertex
Libertex is part of the Libertex Group and is an online broker offering tradable CFDs whose underlying assets are commodities, foreign exchange, ETFs, cryptocurrencies and others.
Over the years, Libertex has received more than 40 prestigious international awards and recognitions, including "Best CFD Broker Europe" (Global Brands Magazine, 2022) and "Most Trusted Broker in Europe" (Ultimate Fintech Awards, 2021). Libertex is the Official Online Trading Partner of FC Bayern and Tottenham Hotspur FC, bringing together the exciting worlds of football and trading.
Since its inception in 1997, the Libertex Group has grown into a diverse group of companies serving millions of customers from different countries around the world.
The Libertex trading platform is used by Indication Investments Ltd, a Cypriot investment firm regulated and supervised by the Cyprus Securities and Exchange Commission (CySEC) with CIF license number 164/12.
For more information about Libertex, please visit libertex.com
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 62.2% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
VIDEO: https://youtu.be/jCCVfHUzrDo
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005297/en/
Contact information
Press Contact:
Action PR
Evri Fotiadou
evri.f@actionprgroup.com
phone: +357 22 818724
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom